Skip to main content
HCPCS J0202 · Level II · Part B drug

J0202: alemtuzumab (Lemtrada), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0202

Billing unit
1 MG
Injection, alemtuzumab
ASP payment limit
$2,506.20
October 2026; -1.5% vs July 2026
Practitioner MUE
12
MAI 3
OPPS status
SI K
APC 1809
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS J0202 is the Level II code for Injection, alemtuzumab, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $2,506.20 per billing unit, down 1.5% from July 2026. The practitioner MUE allows up to 12 units per date of service (MAI 3), so a full 12-unit day is $30,074.40 at the current limit. Under OPPS it carries status indicator K in APC 1809. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 1 NDC to it, sold as Lemtrada by Genzyme Corporation. 1 Medicare coverage article lists the code across 4 states, including A55310.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0202 at $2,506.20 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2,544.937 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J0202
QuarterPayment limitPerCoinsurance
October 2026$2,506.201 MG20%
July 2026$2,544.9371 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J0202. Report the NDC in the claim's drug segment and bill the number of J0202 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J0202
NDCDrug nameLabelerPackage sizeBilling units / package
58468-0200-01LemtradaGenzyme Corporation1.2 × 112

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0202. For practitioners the limit is 12 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0202 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services123 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital123 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J0202 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0202 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0202 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0202 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J0202 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J0202
ArticleTitleContractor(s)StatesRelated LCD
A55310Billing and Coding: Instructions for Lemtrada® (alemtuzumab) When Used in the Treatment of Relapsing Multiple SclerosisPalmetto GBANC SC VA WV—

Diagnoses Medicare contractors cover for J0202

One billing and coding article attaches a covered diagnosis list to J0202: 2 distinct ICD-10-CM codes in all. The 2 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 2 covered ICD-10-CM codes for J0202
ICD-10-CMDescription (FY2027)Articles covering
G35.ARelapsing-remitting multiple sclerosis1 of 1
G35.C1Active secondary progressive multiple sclerosis1 of 1

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J0202 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J0202, by article
ArticleContractorGroups that applyCovered codes for J0202Full list
A55310Palmetto GBAone list for every code in the article2Open the list

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0202 carries status indicator K and is assigned to APC 1809, with a published national unadjusted payment of $2,506.20. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0202 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $2,506.20 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J0202 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0202

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0202

What does HCPCS code J0202 describe?

J0202 is defined by CMS as "Injection, alemtuzumab, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0202 a CPT code?

No. J0202 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as alemtuzumab (Lemtrada); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0202 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0202 in October 2026?

The ASP-based payment limit is $2,506.20 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2,544.937. Commercial payers use their own fee schedules.

How many units of J0202 can be billed per day?

The practitioner Medically Unlikely Edit is 12 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J0202?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Lemtrada (Genzyme Corporation). For example NDC 58468-0200-01 (package size 1.2) equals 12 billing units of J0202.

Does J0202 have NCCI bundling edits?

No active practitioner PTP pairs list J0202 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J0202?

1 current Billing and Coding Article in the Medicare Coverage Database lists J0202, covering 4 states: A55310 (Billing and Coding: Instructions for Lemtrada® (alemtuzumab) When Used in the Treatment of Relapsing Multiple Sclerosis).

What diagnosis codes support J0202?

One Medicare billing and coding article lists 2 covered ICD-10-CM codes for J0202, for example G35.A (Relapsing-remitting multiple sclerosis); G35.C1 (Active secondary progressive multiple sclerosis). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.